-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Reiterates Outperform on Zenas BioPharma, Maintains $45 Price Target

Benzinga·09/30/2026 12:28:03
Wedbush analyst Martin Fan reiterates Zenas BioPharma (NASDAQ:ZBIO) with a Outperform and maintains $45 price target.